SCHEMBL19974925

SCHEMBL19974925

CC(C(O)C(=O)NCC1CC1)N(C=O)c1ccccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2D6 P10635 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
TP53 P04637 1/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PTGIR P43119 1/20 0.38
F10 P00742 3/20 0.36
PRSS1 P07477 3/20 0.36
CHRM1 P11229 1/20 0.35
GRM5 P41594 1/20 0.35
DRD2 P14416 1/20 0.35
CNR2 P34972 2/20 0.34
PSEN1 P49768 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974932 0.88 L3MBTL1 (0.38) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL19974960 0.87 PTGIR (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL19975274 0.85 PTGIR (0.41) MEN1KMT2ACYP2C19ALDH1A1GAA
SCHEMBL28875780 0.85 F10 (0.39) MEN1KMT2AF10PRSS1
SCHEMBL19975415 0.85 HPGD (0.42) TP53SMN1; SMN2ALDH1A1GAAL3MBTL1
SCHEMBL19974938 0.83 SMN1; SMN2 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL19975296 0.81 ALDH1A1 (0.38) TP53SMN1; SMN2ALDH1A1GAAL3MBTL1
SCHEMBL19975062 0.81 ALDH1A1 (0.48) MEN1KMT2ATP53SMN1; SMN2ALDH1A1
SCHEMBL19974871 0.81 MEN1 (0.39) MEN1KMT2ACYP3A4CYP2D6CYP2C9
SCHEMBL19975353 0.81 BCHE (0.45) MEN1KMT2ASMN1; SMN2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C MEN1 4331/4885KMT2A 4031/4885CYP3A4 2207/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C MEN1 4361/4885KMT2A 4177/4885CYP3A4 1986/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C MEN1 4331/4885KMT2A 4031/4885CYP3A4 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.